Alzheimer’s & Dementia

Filter Your Results




Long-Term Safety and Efficacy of Valbenazine for Patients With Tardive Dyskinesia

Monday, August 20, 2018—Long-term results for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), a treatment for patients with tardive dyskinesia (TD), are being presented at the 2018 Wor…

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

Wednesday, August 08, 2018—A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of perso…

Braintest App Has Equivalent Sensitivity and Specificity as SAGE Test for Mild Cognitive Impairment

Tuesday, August 07, 2018—There is an app (BrainTest, Columbus, OH) used to detect mild cognitive impairment (MCI). It is a clinically validated, digital version of the paper and pen Self-Administered …

Aggressive Treatment of Hypertension Promotes Healthy Brains and Hearts

Monday, July 30, 2018—Aggressive lowering of systolic blood pressure (BP) reduces the risk of mild cognitive impairment (MCI) and combined MCI and dementia. In the SPRINT trial (NCT01206062), 2 str…

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

Monday, July 30, 2018—In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safel…

Positive Results in Phase 2 Trial of BAN2401 for Treatment of Persons With Alzheimer’s Disease

Friday, July 27, 2018—Detailed results of a phase 2 study (NCT01767311) of BAN2401 (Eisai, Woodcliff Lake, NJ and Biogen, Cambridge, MA) were presented at the Alzheimer's Association Internatio…

Phase 2/3 Clinical Trial of Trigriluzole for Alzheimer's Disease Initiated

Thursday, July 26, 2018—A Phase 2/3 clinical trial of trigriluzole (BHV-4157; Biohaven, Cambridge, MA for treatment of patients with mild-to-moderate Alzheimer's disease (AD) has been initiated i…

Crenezumab and Gantenerumab In Phase 3 Trials for Treating Persons with Alzheimer’s Disease

Thursday, July 26, 2018—Crenezumab and Gantenerumab are 2 monoclonal antibodies directed against amyloid-ß (Aß) soluble and oligomeric forms. Crenezumab more specifically targets oli…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.